1. LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial. (23rd January 2014) Authors: Gabay, C.; Emery, P.; van Vollenhoven, R.; Dikranian, A.; Alten, R.; Klearman, M.; Musselman, D.; Agarwal, S.; Green, J.; Kavanaugh, A. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0137 Risk factors for major adverse cardiovascular (CV) events (MACE) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ). (23rd January 2014) Authors: Rao, V.U.; Pavlov, A.; Klearman, M.; Musselman, D.; Giles, J.T.; Bathon, J.M.; Sattar, N.; Lee, J.S. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 356 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗